10x Genomics acquired Epinomics, Inc. for $22.2 million, a transaction completed in August 2018, structured as Stock/asset acquisition (terms not disclosed).
Epinomics, Inc. operates in Epigenetics / Single Cell, is based in California, United States. Acquisition of Epinomics, Inc., a California-based epigenetics company founded by the team that developed the ATAC-seq technology, giving 10x Genomics foundational ATAC-seq technology and intellectual property. This was 10x Genomics' first acquisition.
Accelerate discoveries in epigenomics and provide a foundation for new products; technology was immediately integrated into 10x's Chromium Single Cell ATAC Solution.
ATAC-seq IP and technology integrated into 10x's Chromium Single Cell ATAC Solution. Chromium Single Cell platform
Today's acquisition gives us a strong team, IP and technology that has been enthusiastically validated by customers. It provides a foundation for powerful new products and positions us well to become the leader in epigenomics.Serge Saxonov, CEO and co-founder of 10x Genomics
We are excited to be joining forces with 10x Genomics to transform research and advance healthcare by leveraging cutting-edge scientific technology and deep data analytics.Fergus Chan, co-founder and CEO of Epinomics
Advisory firms were not disclosed for this transaction.